Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
Conditions: Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer Interventions: Drug: Fulvestrant; Drug: Anastrozole; Drug: Abemaciclib Sponsor: University of California, Irvine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2022 Category: Research Source Type: clinical trials
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
Conditions: Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer Interventions: Drug: Fulvestrant; Drug: Anastrozole; Drug: Abemaciclib Sponsor: University of California, Irvine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2022 Category: Research Source Type: clinical trials
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
Conditions: Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer Interventions: Drug: Fulvestrant; Drug: Anastrozole; Drug: Abemaciclib Sponsor: University of California, Irvine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2022 Category: Research Source Type: clinical trials
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Condition: Breast Neoplasms Interventions: Drug: Imlunestrant; Drug: Tamoxifen; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane Sponsor: Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 24, 2022 Category: Research Source Type: clinical trials
